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INTRODUCTION
Preterm premature rupture of membranes (PPROM) is
defined as rupture of the fetal membranes before the onset
of labor at less than 37 weeks gestation. The incidence of
PPROM is approximately 1% of all pregnancies and about
30% of all preterm deliveries (1, 2). Cox and associates (3)
reported that this complication was identified in only a small
number of pregnancies but its contribution to perinatal death
was significant. Although a substantial amount of research
has been performed to study the management of PPROM
(4-8), no consensus on the management of this disease exists.
Approximately 75% of these women will deliver within 1
week of presentation (4) and average time gained with treat-
ment was about 10 days (6). The most common complica-
tions of neonates include respiratory distress syndrome (RDS),
intraventricular hemorrhage (IVH), necrotizing enterocoli-
tis (NEC), and sepsis. The maternal risks include the uter-
ine infection and its sequela. 
The primary entry point for neonatal morbidity and mor-
tality among preterm infants is RDS and its complications,
the most important risk factor (9). Liggins observed that lambs
born preterm after exposure to corticosteroids in utero sur-
vived longer than lambs that did not (10). Liggins and Howie
first described the antenatal administration of corticosteroids
for the acceleration of fetal pulmonary maturity in 1972 (11).
Subsequently, various randomized controlled trials confirmed
the benefits of antenatal corticosteroids given to mothers who
were at risk of premature delivery (9, 11-14), which, substan-
tially decreased the risk of RDS in preterm newborns. Mater-
nal administration of corticosteroids has served as the prima-
ry therapeutic approach to RDS prevention. On the basis of
these numerous studies, the National Institutes of Health
(NIH) concluded that antenatal corticosteroid therapy is indi-
cated for women at risk of premature delivery with few excep-
tions (15). NIH also reports that antenatal corticosteroid ther-
apy is effective, even on extremely low birth weights, how-
ever not conclusive because not enough studies have been
completed. One study reported that the incidence of IVH,
delivered between 24 and 28 weeks of gestation, was reduced
in the betamethasone group (7). However, there was insuffi-
cient data on pregnancies of less than 28 weeks gestation to
confidently state the limits of efficacy of antenatal corticos-
teroid therapy. 
Several investigators observed that antibiotics reduced the
incidence of intrauterine infection after PPROM, demonstrat-
ed the prolongation of gestation, and a decrease in the rate
of neonatal complications (4, 16-25). Mercer et al. reported
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Effect of Antenatal Corticosteroid and Antibiotics in Pregnancies
Complicated by Premature Rupture of Membranes between 24 and
28 weeks of Gestation
The aim of this study was to assess the effectiveness of active intervention with
antenatal maternal corticosteroid and antibiotics therapy in infants delivered between
24 and 28 weeks of gestation after premature rupture of membrane. This retro-
spective study included pregnant women complicated by preterm delivery at the
Dong-A University Hospital from 1998 to 2002. Patients were divided into labor
induction group 1 (n=20), observation group 2 (n=19), and medication group 3
(n=20). We evaluated the effects of prolongation of pregnancy and intervention
with maternal corticosteroids and antibiotics therapy on perinatal and neonatal out-
comes. Each group did not have a significant difference (p<0.05) in neonatal out-
comes, such as respiratory distress syndrome, intraventricular hemorrhage, necro-
tizing enterocolitis, retinopathy of prematurity, pneumonia, bronchopulmonary dys-
plasia, and sepsis. The mean latency period was 4.7 days and 7.6 days in groups
2 and 3, respectively. Therefore, this study was unable to demonstrate any benefi-
cial effects of corticosteroids in improving neonatal outcomes and prolongation of
the latency period with antibiotics.
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the benefits of prophylactic antibiotics on parameters such
as a prolonged latency period, significant decreases in neona-
tal sepsis, pneumonia, and IVH (4). Egarter et al. (16) also
confirmed a significant decrease in neonatal sepsis and IVH.
The National Institute of Child Health and Human Devel-
opment (NICHD) and the Maternal Fetal Medicine Net-
work performed a double-blind randomized controlled trial
to investigate if antibiotic therapy during expectant man-
agement for PPROM would reduce neonatal complications.
The results confirmed a prolonged latency period and sig-
nificant reductions of neonatal morbidity and mortality (4).
However, the optimal and most effective treatment is still a
difficult decision, especially for a second trimester ruptured
membranes. Farooqi et al. (6) conducted a  retrospective study
on survival and a 2-yr outcome of second-trimester rupture
of membranes with expectant management. The perinatal
survival rate was 50% and 88% when membranes ruptured
at 23 to 25 weeks and 26 to 28 weeks, respectively. Thus, the
most important factor in neonatal prognosis may be the ges-
tational age. Numerous studies demonstrated a steady increase
in perinatal survival rate after second-trimester PPROM by
the use of antenatal corticosteroids and also the benefits of
antibiotic therapy (8, 26). However, the management with
these drugs in second-trimester PPROM continues to be
debated. 
Therefore we evaluated the effectiveness of maternal corticos-
teroids and antibiotic therapy in infants delivered between
24 and 28 weeks of gestation complicated by PPROM, as
well as any complications. 
MATERIALS AND METHODS
Material 
This retrospective study included 59 singleton pregnant
women complicated by PPROM between 24 and 28 weeks of
gestation at Dong-A University Hospital from January 1998
to December 2002. Estimated gestational age was determined
by the last menstrual period, if a reliable date was present,
and confirmed with ultrasonography. Those with an unclear
history of the last menstrual period of those with a history of
an irregular menstrual cycle, the dates were revised to match
the ultrasonography checked before 20 weeks of gestational
age. PPROM was diagnosed according to standard clinical
criteria, including the patient’s history, a presence of a vagi-
nal pool, a positive nitrazine test, ferning, and the amounts
of amniotic fluid estimated by ultrasonography. Cases involv-
ing multiple gestation, antepartum stillbirth, induced abor-
tion, active labor defined as frequent uterine contractions
with cervical change, suspected chorioamnionitis on admis-
sion, nonreassuring fetal heart rate patterns at admission, and
birth of an infant with a major congenital malformation were
excluded. 
Methods 
All patients were complicated by preterm delivery between
24 and 28 weeks after PPROM. We evaluated the effects of
maternal dexamethasone therapy and antibiotics therapy on
the perinatal and neonatal outcomes based on the data extract-
ed from the medical records. After a patient was identified
with PPROM and did not meet any of the exclusion criteria,
we divided all patients into 3 groups, labor induction group
(group 1, n=20), observation group (group 2, n=19), and
medication group (group 3, n=20). Group 1 did not receive
any other medication, but only induction of labor with oral
prostaglandin. Group 2 patients only received close moni-
toring of fetal and maternal status while waiting for sponta-
neous labor. Group 3 received parenteral ampicillin therapy,
2.0 g intravenously every 8 hr for 7 days and dexamethasone
therapy, 5 mg intramuscularly every 12 hr for a total of four
doses. We used a single course of dexamethasone therapy in
all patients. In group 2 and 3, we carried out fetal heart rate
monitoring daily and performed ultrasound examination at
least once a week for estimation of fetal size, amniotic fluid
volume, and fetal biophysical profile. Serial checks of maternal
white blood cell (WBC) count and C-reactive protein (CRP)
level on admission were performed. Further speculum exami-
nations were avoided except in the case of regular uterine
contraction. All pregnancies were terminated in cases of sus-
pected maternal infection such as increasing evidence of WBC
count or CRP level, elevation of maternal body temperature
above 37.2℃, excluding any other possible causes of fever,
fetal tachycardia, other clinical evidence of chorioamnionitis,
and abnormal fetal heart rate pattern. In group 1, continuous
fetal heart rate monitoring was performed. Cesarean delivery
was performed in case of fetal compromise in all 3 groups. 
Based on the medical records, we evaluated the clinical
characteristics of the mother and neonate such as maternal
age, parity, cervical condition at admission, amniotic fluid
index at admission, the latency from rupture-to-delivery inter-
val, maternal body temperature before delivery, clinical symp-
toms of chorioamnionitis, gestational age, birth weight, 1
min and 5 min Apgar score, and WBC counts and CRP lev-
els of neonates and those of mothers sampled at least 12 hr
before delivery. Also, we evaluated the incidences of RDS,
IVH, ROP, NEC, pneumonia, BPD and sepsis. RDS was
diagnosed by a neonatologist and required intubation with
oxygen therapy and the classic appearance on a chest radio-
graph. IVH was diagnosed by neurosonographic examination
of the head and was graded according to Papile and colleagues
(27) and ophthalmologic examinations were performed by
ophthalmologist to check for ROP. Neonatal sepsis was diag-
nosed either by positive blood culture, or by a combination
of clinical signs and laboratory findings, such as leucopenia,
thrombocytopenia, and elevated CRP level. All deliveries were
attended by a neonatologist and all infants were admitted to
the neonatal intensive care unit. 90 G.A Song, M.S. Han
Statistical analysis 
Statistical significance was determined using SPSS program
through Pearson’s chi-square test, Fisher’s exact test, ANOVA,
and Student’s t-test. A value of p<0.05 was considered statis-
tically significant. 
RESULTS
There are no significant differences among the groups with
regards to maternal age, gestational age on admission, birth
weight, amniotic fluid index on admission, cervical condition
on admission, mode of delivery, and parity (p>0.05) (Table
1). Table 2 demonstrates that each group does not differ with
respect to 1 and 5 min Apgar score, neonatal WBC count,
or neonatal CRP level. However, we found significant dif-
ferences in WBC count, CRP level and body temperatures
of the mothers at delivery (p<0.05). Maternal WBC count
and CRP level were much more different between groups 2
and 3 (p=0.007). We rationalize that antibiotics and corticos-
teroids can reduce the maternal morbidity from infections
when delivery is delayed. Maternal body temperature at deliv-
ery of group 2 is higher than that of group 1 and 3 (p<0.05).
The elevated body temperature may be related with mater-
nal infection. The mean latency period of group 2 is 4.7 days
and of group 3 is 7.6 days (p>0.05) (Table 2). The prolonged
latency period of group 3 compared to group 2 may be at-
tributed to the antibiotics; however, this was not statistical-
ly significant. 
Table 3 reveals the neonatal complications of each group.
In each of the complications, there are no statistically signif-
icant differences among the 3 groups (p>0.05). We cannot
demonstrate that any other intervention, including antenatal
corticosteroid and antibiotic therapy, even the prolongation
of gestational age by waiting for spontaneous labor, improves
the neonatal outcomes.
DISCUSSION 
Women, who present with signs and symptoms of impend-
ing preterm delivery, are candidates for various interventions
intended to improve infant outcomes. Interventions include
antenatal corticosteroid therapy with or without antibiotic
therapy. Both randomized studies and meta-analysis (28, 29)
have shown that maternal corticosteroid administration reduces
the risks of neonatal RDS, IVH, NEC and neonatal death, to
a lesser extent, in preterm deliveries. However, the efficacy of
impending preterm delivery is not well established because
of insufficient data. Garite et al. (7), in a randomized controll-
ed study, reported that antenatal corticosteroids did not im-
prove perinatal outcomes and was not associated with mater-
nal infection-related complications. They achieved statisti-
cally significant differences in the incidence of grade 3 and 4
IVH. Neonates born to women who received corticosteroids
had a 3% incidence of IVH, whereas neonates born to women
assigned to the placebo had a 25% incidence. However, the
study groups were limited to babies delivered between 24
and 28 weeks gestation with intact membrane, not compli-
S.D., Standard deviation; GA, Gestation age; BWt, Birth weight; AFI,
Amniotic fluid index; Cx, Cervix; NS, Not significant; P, Primiparity; M,
Multiparity; Group 1, labor induction group; Group 2, observation group;
Group 3, medication group.
p-value
Group 3
(n=20)
Group 2
(n=19)
Group 1
(n=20)
Maternal age (yr) 31.5±3.7 31.2±5.2 30.9±4.7 NS
GA at admission 26±1
+2 26±1
+2 26±1
+1 NS
(weeks)
BWt (gm) 971.0±129.4 972.9±115.4 974.5±186.8 NS
AFI (cm) 7.7±2.8 7.2±3.1 8.0±3.4 NS
Cx at admission 1.6±1.2 1.2±1.0 1.3±2.0 NS
(cm)
Cesarean section (%)    60 38.9 70 NS
Parity (P:M) 11:9 12:7 16:4 NS
Table 1. General characteristics of the 3 groups  (mean±S.D.)
RDS, Respiratory distress syndrome; IVH, Intraventricular hemorrhage;
NEC, Necrotizing enterocolitis; ROP, Retinopathy of prematurity; BPD,
Bronchopulmonary dysplasia; Group 1, labor induction group; Group
2, observation group; Group 3, medication group.
*, Fisher’s exact test used to calculate p-values.
p-value
Group 3
(%)
Group 2
(%)
Group 1
(%)
RDS 9/20 (45) 10/19 (52.6) 9/20 (45) NS
IVH 6/20 (30) 5/19 (26.3) 7/20 (35) NS
NEC 2/20 (10) 2/19 (10.5) 3/20 (15) NS
ROP 11/20 (55) 13/19 (68.4) 11/20 (55) NS
Pneumonia* 1/20 (5) 2/19 (10.5) 1/20 (5) NS
BPD 4/20 (20) 9/19 (47.4) 5/20 (25) NS
Sepsis* 1/20 (5) 2/19 (10.5) 1/20 (5) NS
Table 3. Neonatal complications of the 3 groups
S.D., Standard deviation; WBC, White blood cell; CRP, C-reactive pro-
tein; NS, Not significant; GA, Gestational age; Group 1, labor induction
group; Group 2, observation group; Group 3, medication group.
*, Student’s t-test.
p-value
Group 3
(n=20)
Group 2
(n=19)
Group 1
(n=20)
1 min Apgar score<7 15 (75%) 15 (79%) 14 (70%) NS
5 min Apgar score<7 5 (25%) 6 (33%) 4 (20%) NS
Neonatal WBC (×10
3) 18.5±15.8 15.5±12.1 10.7±8.4 NS
Neonatal CRP (ng/dL) 0.32±0.11 0.37±0.08 0.35±0.13 NS
Maternal WBC (×10
3) 7.1±4.1 15.3±4.5 11.3±3.0 0.010
Maternal CRP (ng/dL) 0.49±0.06 0.96±0.14 0.58±0.09 0.021
GA at delivery (weeks) 26±1
3 27±1
1 27±1
3 NS
Body temperature (℃) 36.9±0.54 37.4±0.56 36.9±0.36 0.004
Latency* (days) 4.74±6.65 7.60±8.67 NS
Table 2. Clinical characteristics of the 3 groups   (mean±S.D.)Antenatal Corticosteroid and Antibiotics in PPROM 91
cated by PPROM. Another study showed that antenatal cor-
ticosteroid therapy reduced the severity of IVH (30). In a one
year prospective observational study, Chapman et al. (31) con-
cluded that corticosteroid treatment did not have an appar-
ent benefit. They focused on infants delivered at ≤29 weeks’
gestation and weighing ≤1,000 g at birth whose mothers
were seen for PPROM. 
In our study, the incidences of RDS were 45%, 52.6%, and
45% in group 1, 2, and 3, respectively. Significant differences
among the 3 groups were not detected. 
Although IVH shows a higher incidence in group 3 (35%)
than group 2 (26.3%), it was not statistically significant. The
severity of IVH among the different groups was not analyzed.
The use of antenatal corticosteroid in patients with PPROM
has been cautious, because of the fear that it may worsen an
infection and its complications. One can hypothesize that
antibiotic therapy would be important in decreasing the infec-
tious morbidity associated with the immunocompromised
state that results from steroid use in patients with PPROM.
However, concomitant use of corticosteroids and antibiotics
has been debated and is controversial. Leitich et al. (8) con-
cluded that the beneficial effects of antibiotics in PPROM
might be diminished when glucocoticoids are used concomi-
tantly. Hence, a careful selection of patients who were likely
to benefit from both therapies was needed (8). Lewis et al. (32)
suggested that the use of broad-spectrum antibiotic before
corticosteroids was beneficial to the babies without an increased
risk of infectious morbidity. They hypothesized that if infec-
tion is the most likely etiology of PPROM, the antibiotics
initially could be used to control the infection before adminis-
tering a drug, corticosteroid, that could cause immumosup-
pression. They gave corticosteroid at least 12 hr after receiv-
ing antibiotics. However, the optimum period of duration
of antibiotic therapy before administering steroids remains
to be determined. In our study, we also administered antibi-
otics followed by corticosteroid, but we did not have a strict
time of duration. Hence, this point remains to be studied fur-
ther. However group 2 revealed an increased sign of infections
such as elevation of WBC count, CRP level, and body tem-
perature which may be due to the lack of antibiotic use. But,
we could not estimate the effects of concomitant use of cor-
ticosteroid precisely. When comparing group 1 and group
3, there is no evidence of immunosuppression in group 3. The
p-value of maternal WBC count, CRP level, and body tem-
perature between group 1 and 3 are 0.382, 0.685, and 0.955,
respectively, which are not statistically significant. Thus, the
concomitant use of corticosteroid may not reduce the bene-
ficial effects of antibiotics. The 2000 NIH consensus devel-
opment conference recommended that repeat courses of ante-
natal corticosteroids should be reserved for patients enrolled
in clinical trials. In our study, we use a single course method
in all patients. 
Numerous studies suggested that the use of antibiotics
reduced the incidence of intrauterine infection after PPROM,
other neonatal complications, and also could prolong the laten-
cy period (4, 16-25). Approximately 75% of women will be
delivered within 1 week of presentation (4) and average time
gained was about 10 days (6). In our study, the mean laten-
cy period of group 2 is 4.7 days and 7.6 days in group 3. A
trend towards prolongation of the latency period when treat-
ed with antibiotics was noted, even though the difference is
not statistically significant (p>0.05). Our average time gained
is shorter than other previous reports (6). In one case, the max-
imum time gained was 30 days. This patient had a history
of null parity and had adequate amniotic fluid volume. 
Many centers have adopted some variation of the antibiot-
ic regimen and its therapeutic duration. The NICHD used
2 days of parenteral antibiotics versus 5 days of oral antiboitics.
Segel et al. (33) studied the effect of antibiotic treatment dura-
tion. They performed a randomized clinical trial comparing
3 days of ampicillin versus 7 days of ampicillin in patients
with PPROM. They concluded that a shorter course of antibi-
otics could have the same effect on latency as a 7 day course
without increasing of the incidence of infection-related com-
plications and neonatal morbidity. We used ampicillin via
the parenteral route as the primary antibiotic for a total dura-
tion of 7 days.
Unfortunately, we cannot make clear management recom-
mendations for PPROM. Corticosteroids seem to be benefi-
cial at gestational ages >28 weeks to decrease neonatal mor-
bidity and mortality from RDS and IVH, but it seems to be
ineffective between 24 and 28 weeks as shown in our study
and other reports. If RDS is the primary entry point for neona-
tal morbidity and mortality among preterm infants, the im-
portant point of management is the prolongation of latency
period. We can extend the time of latency by using antibi-
otics without increasing the evidence of infectious morbidi-
ty. However, we also used corticosteroid concomitantly with
antibiotics, it is difficult from our data to estimate the effects
of corticosteroids on our prolonged latency. A need exists for
a prospective study to clarify this point. 
Although it is very hard to make a clear conclusion in the
management of second-trimester PPROM from our data,
seems to increase the time of latency without increasing infec-
tious morbidity. However, it is not effective on neonatal com-
plications. This may be due a very small sample size. Thus,
the further studies with large sample size are warranted. 
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